Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec;80(12):3454-3457.
doi: 10.1111/all.70001. Epub 2025 Aug 2.

Associations Between Blood Eosinophil Surface Proteins and Clinical Traits in Severe Asthma and Chronic Rhinosinusitis With Nasal Polyposis

Emeline Delaunay  1   2 , Stephane Esnault  1   2   3 , Arnaud Dendooven  1   2 , Thomas Stoup  4 , Thibaut Vanderhaegen  5 , Louison Jan  5 , Laurine Cadart  6 , Cecile Chenivesse  7   8 , Geoffrey Mortuaire  1   5 , Guillaume Lefèvre  1   2
Affiliations

Associations Between Blood Eosinophil Surface Proteins and Clinical Traits in Severe Asthma and Chronic Rhinosinusitis With Nasal Polyposis

Emeline Delaunay et al. Allergy. 2025 Dec.
No abstract available

Keywords: CRSwNP; disease severity; eosinophils; severe asthma; surface protein expression.

PubMed Disclaimer

Conflict of interest statement

C. Chenivesse declares research grants from AstraZeneca, GSK, Santelys, and Novartis; personal fees from ALK‐Abello, AstraZeneca, Boehringer‐Ingelheim, Celtrion, Chiesi, Sanofi, and GSK; and congress support from AstraZeneca, Boehringer Ingelheim, Chiesi, Sanofi, and Novartis. G. Lefèvre received consulting fees, personal fees for advisory boards or meetings, and research funding from AstraZeneca and GSK. The rest of the authors declare that they have no relevant conflicts of interest.

Figures

FIGURE 1
FIGURE 1
CD125 expression and marker correlations in severe asthma and CRSwNP. (A) Difference in expression of CD125 MFI (median fluorescent intensity) between the three groups: Healthy control (HC), severe asthma (SA) and CRSwNP (n = 19 HC; 24 SA; 14 CRSwNP). Adjustments were made for age and gender. Statistical analyses were performed with a ANCOVA test (*p < 0.05, ns = not significant). (B, C) Matrix of correlations between the expression of surface markers on blood eosinophils and the clinical score from the group (B) severe asthma and (C) CRSwNP. Correlations were calculated using Spearman's method. Statistical correlations (p < 0.05) are represented by brighter colours. CD62‐L, CD123 and Siglec‐8 were removed from the analysis for the CRSwNP group due to insufficient data. ACQ‐6, Asthma Control Questionnaire; ACT, Asthma Control Test; CRSwNP, chronic rhinosinusitis with nasal polyps; CT Lund MacKay, CT scan score of sinus opacification; eosinophils, eosinophils count in the blood; FeNO, fractioned exhaled nitric oxide; FEV1/FVC, forced exhaled volume in 1 s/forced vital capacity; NPS, nasal polyp score; p, p‐value of the test; R, Spearman factor; SNOT 22, Sino‐Nasal Outcome Test; VAS, visual analogic scale.
See this image and copyright information in PMC

References

    1. Striz I., Golebski K., Strizova Z., et al., “New Insights Into the Pathophysiology and Therapeutic Targets of Asthma and Comorbid Chronic Rhinosinusitis With or Without Nasal Polyposis,” Clinical Science (London, England) 137 (2023): 727–753, 10.1042/CS20190281. - DOI - PMC - PubMed
    1. Sood V., Rogers L., and Khurana S., “Managing Corticosteroid‐Related Comorbidities in Severe Asthma,” Chest 160 (2021): 1614–1623, 10.1016/j.chest.2021.05.021. - DOI - PubMed
    1. Eger K., Kroes J. A., Ten Brinke A., and Bel E. H., “Long‐Term Therapy Response to Anti‐IL‐5 Biologics in Severe Asthma‐A Real‐Life Evaluation,” Journal of Allergy and Clinical Immunology. In Practice 9 (2021): 1194–1200, 10.1016/j.jaip.2020.10.010. - DOI - PubMed
    1. Dezoteux F., Marcant P., Dendooven A., et al., “Enhanced Siglec‐8 and HLA‐DR and Reduced CRTH2 Surface Expression, Highlight a Distinct Phenotypic Signature of Circulating Eosinophils in Atopic Dermatitis,” Journal of Leukocyte Biology 117 (2025): qiaf023, 10.1093/jleuko/qiaf023. - DOI - PubMed
    1. Kiwamoto T., Kawasaki N., Paulson J. C., and Bochner B. S., “Siglec‐8 as a Drugable Target to Treat Eosinophil and Mast Cell‐Associated Conditions,” Pharmacology & Therapeutics 135 (2012): 327–336, 10.1016/j.pharmthera.2012.06.005. - DOI - PMC - PubMed

Grants and funding

LinkOut - more resources